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Abstract
Background
International Sustainable Development Goals (SDGs) for elimination of hepatitis B virus
(HBV) infection set ambitious targets for 2030. In African populations, infant immunisation
has been fundamental to reducing incident infections in children, but overall population
prevalence of chronic hepatitis B (CHB) infection remains high. In high-prevalence popula-
tions, adult catch-up vaccination has sometimes been deployed, but an alternative Test
and Treat (T&T) approach could be used as an intervention to interrupt transmission. Uni-
versal T&T has not been previously evaluated as a population intervention for HBV infec-
tion, despite high-profile data supporting its success with human immunodeficiency virus
(HIV).
Methods and findings
We set out to investigate the relationship between prevalence of HBV infection and expo-
sure in Africa, undertaking a systematic literature review in November 2019. We identified
published seroepidemiology data representing the period 1995–2019 from PubMed and
Web of Science, including studies of adults that reported prevalence of both hepatitis B
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Data Availability Statement: Data from the
systematic literature review to determine the
surface antigen (HBsAg; prevalence of HBV infection) and antibody to hepatitis B core anti-
gen (anti-HBc; prevalence of HBV exposure). We identified 96 studies representing 39 Afri-
can countries, with a median cohort size of 370 participants and a median participant age of
34 years. Using weighted linear regression analysis, we found a strong relationship between
the prevalence of infection (HBsAg) and exposure (anti-HBc) (R2 = 0.45, p < 0.001).
Region-specific differences were present, with estimated CHB prevalence in Northern Africa
typically 30% to 40% lower (p = 0.007) than in Southern Africa for statistically similar expo-
sure rates, demonstrating the need for intervention strategies to be tailored to individual set-
tings. We applied a previously published mathematical model to investigate the effect of
interventions in a high-prevalence setting. The most marked and sustained impact was pro-
jected with a T&T strategy, with a predicted reduction of 33% prevalence by 20 years (95%
CI 30%–37%) and 62% at 50 years (95% CI 57%–68%), followed by routine neonatal vacci-
nation and prevention of mother to child transmission (PMTCT; at 100% coverage). In con-
trast, the impact of catch-up vaccination in adults had a negligible and transient effect on
population prevalence. The study is constrained by gaps in the published data, such that we
could not model the impact of antiviral therapy based on stratification by specific clinical cri-
teria and our model framework does not include explicit age-specific or risk-group assump-
tions regarding force of transmission.
Conclusions
The unique data set collected in this study highlights how regional epidemiology data for
HBV can provide insights into patterns of transmission, and it provides an evidence base for
future quantitative research into the most effective local interventions. In combination with
robust neonatal immunisation programmes, ongoing PMTCT efforts, and the vaccination of
high-risk groups, diagnosing and treating HBV infection is likely to be of most impact in driv-
ing advances towards elimination targets at a population level.
Author summary
Why was this study done?
• Hepatitis B virus (HBV) infection is a major global health problem, with an estimated
290 million infections worldwide; international targets set the challenge for this public
health threat to be eliminated by 2030.
• Administering HBV vaccine to babies is a very successful way to prevent new infections,
but previous studies have shown that this strategy will take many decades to bring about
elimination targets.
• We set out to investigate other approaches that can be used in combination with the
infant vaccination schedule, using data from a meta-analysis and modelling the impact
of vaccinating older children and adults, or enhancing testing and treatment (T&T) of
existing HBV infections.
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What did the researchers do and find?
• We undertook a review and meta-analysis of all the published data describing the fre-
quency of HBV infection, as well as the frequency of exposure to HBV infection in Afri-
can populations, working with data from 96 studies published between 1995 and 2019.
• Using these data, we demonstrated a significant relationship between exposure
and infection (overall p< 0.001) and identified differences between geographic
regions.
• Using an existing mathematical model, our findings suggest that vaccinating older age
groups has negligible sustained effect on HBV rates in a population, but universal T&T
of HBV is predicted to have a substantial impact.
What do these findings mean?
• Our results show different patterns of HBV infection and transmission in different
regions of Africa, illustrating that interventions may need to be tailored according to the
specific setting.
• We have demonstrated that vaccination campaigns targeting older children and adults
are unlikely to be an effective use of resources in most African populations, and that
resources are better diverted to improving diagnosis and treatment of existing
infections.
• The study is limited by gaps in existing data, such that many populations in Africa are
poorly represented. Our conclusions are drawn from the output of a model and will
need to be validated in clinical practice.
Introduction
There is an estimated global burden of 290 million cases of hepatitis B virus (HBV) infection
[1], the majority of which are undiagnosed and untreated [2]. Prevalence of HBV exposure
and chronic hepatitis B (CHB) infection are extremely high in some settings in Africa [3, 4].
Robust epidemiology data are lacking, and some populations in Africa have specific vulnera-
bilities associated with poverty, stigma, and co-endemic human immunodeficiency virus
(HIV) infection [2]. Horizontal transmission within households, particularly affecting young
children, is a significant acquisition route in some African populations [5, 6], but the specific
mechanism and timing of transmission remain uncertain in many cases.
Vaccination to protect against infection is a cornerstone of interventions, with enhanced
efforts arising as a result of United Nations (UN) Sustainable Development Goals (SDGs) set-
ting out elimination targets for the year 2030 [7]. Vaccination is included in the Expanded
Programme for Immunization (EPI) and has been progressively rolled out for infants across
Africa since 1995, alongside enhanced interventions for the prevention of mother to child
transmission (PMTCT) [8]. However, despite 2 decades of vaccine implementation, CHB
remains endemic in many regions, and published mathematical models exploring the impact
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of existing interventions demonstrate time scales for success that are substantially beyond the
2030 targets [9, 10].
Treatment of CHB is typically based on nucleoside/nucleotide analogue (NA) drugs,
among which tenofovir disoproxil fumarate (TDF) is the most affordable, accessible, and
widely recommended [8, 11–13]. NA agents have a high rate of success in suppressing detect-
able viraemia, but do not tackle the liver reservoir of virus (in the form of covalently closed
circular DNA (cccDNA) in the nucleus of infected hepatocytes [14]), so most individuals are
committed to long-term treatment. Individuals with CHB are assessed for treatment based on
algorithms that stratify the long-term risk of liver disease based on age and sex, laboratory
measurement of liver enzymes and HBV DNA viral load, elastography scores, or other imaging
data [11–13]. Treatment guidelines also recognise and support the use of TDF during preg-
nancy as part of an approach to reduce vertical transmission [13], and this approach is widely
accepted (albeit variably deployed) [15]. However, there is less recognition of the wider poten-
tial for NA agents to be deployed as a public health intervention to reduce new incident cases.
Tackling the large, chronic population reservoir of HBV in adults is important, and various
strategies are employed to reduce new incident infections in adults. There is an interesting
conflict between formal recommendations and public health policies that are deployed in prac-
tice. Although evidence suggests that ‘catch-up’ vaccination campaigns are likely to have lim-
ited population benefit [9] and are not endorsed by guidelines [8], the strategy can appear an
attractive public health approach for older children and adults in high-prevalence populations
[16] and has been undertaken in some settings [17]. Economic analyses have reported that
catch-up campaigns in young adults are cost-effective only if combined with screening [18],
highlighting the importance of focusing not only on prevention but also on investment in
diagnosis and treatment [19]. The latter concept has been embraced for HIV under the ban-
ners of Treatment for Prevention (T4P) and, more recently, Universal Test and Treat (T&T)
[20], recognising that antiretroviral treatment (ART) confers benefits both to the individual
and also to populations by reducing the risk of transmission [21, 22].
Building on this experience from HIV, a T&T HBV strategy could offer substantial advan-
tages. The feasibility, acceptability, and public health consequences of this approach have been
discussed in reports of HBV treatment deployment in The Gambia [19, 23], although previous
approaches treat only selected individuals deemed to be at highest risk. Evidence-based consid-
eration of the impact of population-level interventions, including more inclusive approaches
for treatment of a greater proportion of all individuals with HBV, are urgently required if we
are to accelerate progress towards elimination targets.
We used a systematic literature review to investigate the seroepidemiology of HBV across
the African subcontinent in order to highlight regional differences and inform local strategies,
with a specific focus on interventions that target adults. Recognising that catch-up campaigns
are already being deployed in some locations, we considered the evidence for any benefit of
this approach, and in parallel, we assessed the impact of universal T&T using epidemiological
data and a mathematical model [9].
Methods
HBV seroepidemiology for Africa
We undertook a systematic search of PubMed and Web of Science in November 2019, using
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria to
underpin a predefined protocol for data collection (Fig 1; S1 PRISMA Checklist). We used the
search terms ‘HBV antibody,’ ‘anti-HBc,’ ‘HB core antibody,’ ‘HBV exposure,’ or ‘HBV preva-
lence’ AND ‘Africa’ or [Name of specific country], using the UN geoscheme for Africa to
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define a list of countries [24]. We assessed the quality of included studies using recommended
criteria from the Joanna Briggs Institute [25, 26]. Inclusion criteria were as follows:
• Data gathered after widespread roll-out of infant vaccination in 1995
• No reported data collection undertaken pre 1995
• Reported prevalence of both hepatitis B surface antigen (HBsAg) and antibody to hepatitis B
core antigen (anti-HBc)
• Cohorts primarily reporting data for adults (age� 16 years)
• Cohort does not sample a population enriched for HBV infection (specific exclusions are
presented in Fig 1)
We recorded anti-HBc prevalence (i.e., proportion of population exposed to HBV, irrespec-
tive of chronic infection status, also termed ‘total exposure’) and also calculated the proportion
Fig 1. PRISMA flowchart showing selection of studies of HBsAg and anti-HBc prevalence in Africa, published
1995–2019, for inclusion in meta-analysis. The analysis included 96 studies; 13 of these studies reported data for 2
discrete cohorts, giving a total of 109 data points included in the final analysis. Anti-HBc, antibody to hepatitis B core
antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PRISMA, Preferred Reporting Items for
Systematic Reviews and Meta-Analyses.
https://doi.org/10.1371/journal.pmed.1003068.g001
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of the population with cleared infection (i.e., anti-HBc prevalence minus HBsAg prevalence,
termed ‘exposed and cleared’). For studies reporting prevalence data from�2 cohorts (e.g.,
HIV-positive and HIV-negative populations), we recorded these as a single publication but�2
discrete data points. We also sought evidence for recommendations underpinning catch-up
vaccination of adolescents and adults in Africa cited in PubMed using the search terms ‘hepati-
tis b virus’ or ‘HBV,’ and ‘Africa’ or [individual country name], with ‘vaccin�’ and ‘catch up’ or
‘adult.’ All studies were evaluated independently by 2 or more authors prior to inclusion in the
analysis.
We set out with 2 prespecified aims, (i) to investigate the relationship between the prevalence
of CHB infection and HBV exposure for different regions of Africa and (ii) to use an existing
model to predict the outcomes of population interventions in a high-prevalence setting.
Statistical analysis of metadata
In order to derive an estimation of the age group represented by the studies included, we used
mean (reported by 48/109 cohorts) and median (reported by 23/109 cohorts). For the remain-
ing 38 cohorts, age was not reported, or the data could not be disaggregated.
The UN geoscheme includes 5 African regions: Central, Eastern, Northern, Southern, and
Western [24]. We analysed prevalence data for anti-HBc and HBsAg using Graphpad Prism
version 7.0 and R. We used weighted linear regression based on cohort size to derive lines of
best fit and 95% confidence intervals and to interpolate data points. We generated maps using
R [27, 28].
Estimates of pooled median proportions (HBsAg positive, anti-HBc), were obtained
through logistic regression with a random intercept assigned to each cohort, performed sepa-
rately for each African region. The 95% confidence intervals of the proportions were based on
profile likelihood of the model’s fixed effect intercepts. Comparisons between different regions
were obtained by sub-setting the data for each pair of regions and creating 2 models. The first
was the logistic regression model with a random intercept assigned to each cohort described
earlier, while the second had an added fixed effect of the study region. These 2 models were
compared through the likelihood ratio test (LRT). The obtained p-values from the LRTs were
then adjusted for multiple comparisons using the Holm-Bonferroni method, and the adjusted
p-values are reported.
Modelling the impact of adult vaccination versus T&T
In this study, we adapted a previously published HBV dynamic model and Markov chain
Monte Carlo (MCMC) approach that we initially developed to fit the seroepidemiology of
Kimberley in South Africa to project the impact of interventions in that transmission setting
[9]; as our mathematical and computational methods are already published, we have not repli-
cated them in this paper. However, for ease of reference, we have provided a summary over-
view of model population classes in Fig 2, as well as relevant parameters in S1 Table.
In this instance, we fitted the model to data from Uganda, a setting of high HBsAg preva-
lence [3]. Target (model-fitted) seroepidemiology variables were HBsAg prevalence at approxi-
mately 10%, anti-HBc prevalence at 42%, and hepatitis B e-antigen (HBeAg) positive relative
prevalence at 27% (S1 Table). We left 4 model parameters free to be fitted to the Uganda set-
ting (with uninformative priors): vertical transmission rate for HBeAg-positive and HBeAg-
negative groups, rate of conversion from HBeAg positive to HBeAg negative, and spontaneous
clearance of chronic HBV infection. The MCMC fitted the model closely to the target variables
at 10% (95% CI 7.92%–11.7%) for HBsAg prevalence, 42.1% (95% CI 40.2%–44.0%) for anti-
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HBc prevalence, and 26.9% (95% CI 24.8%–29.0%) for HBeAg-positive relative prevalence.
The posteriors of the free parameters also closely matched literature expectations (S1 Table).
PMTCT and vaccine-based interventions were modelled as previously described (Fig 2) [9].
As the model framework does not allow for risk stratification beyond age groups, we included
a simple T&T intervention that reduces the transmission potential of the HBV infected pro-
portionally to control effort (e.g., 20% T&T coverage equated to a 20% reduction in the force
of infection). The universal T&T approach thus assumes that HBsAg-positive cases were
treated irrespective of any specific risk stratification.
Results
Studies identified through a systematic literature review
We collated and curated a total of 96 studies spanning 39 African countries and generating
109 unique data points representing independent cohorts (Fig 1; full metadata online at Fig-
share: 10.6084/m9.figshare.6154598). Studies reporting prevalence data from�2 cohorts
(n = 13) are summarised in S2 Table. Across all 109 cohorts, the median number of individuals
sampled was 370 (IQR 177–638, range 50–9,486). The median ages for the cohorts represented
was 34 years (IQR 29–38 years) based on age data reported for 65% of cohorts.
Quality appraisal of data identified through systematic literature review
We undertook a quality assessment of all the studies we identified (full quality appraisal data
online at Figshare: 10.6084/m9.figshare.6154598). The majority of studies included in the
meta-analysis were of good quality, with 85% of studies reporting clear details of the methods
used to measure HBsAg and anti-HBc reflecting our stringent criteria for inclusion of these
Fig 2. Summary diagram of the dynamic model used to fit the seroepidemiology of HBV in Uganda. The naïve (grey rounded boxes) and
vaccinated (blue rounded boxes) subpopulations are divided into 3 relevant age groups: infant (0–1 years), child (1–6 years), and older (+6 years). This
allows us to consider a relationship between the likelihood of developing chronic or acute infection with age (represented by the thickness of the grey
and blue arrows). Individuals can acquire infection in any age group. When acutely infected (yellow rounded box), individuals may clear infection and
recover (green rounded box). When chronically infected, individuals can be HBeAg positive (purple rounded box) and transit to become HBeAg
negative (red rounded box), after which they may recover (green rounded box). Interventions (light blue squared boxes) target different
epidemiological states and transitions (orange circles). Vertical transmission can occur from infected mothers to newborns. Protection mediated by
infant vaccination is age dependent due to waning and is assumed to lower susceptibility to infection. Parameters are listed in S1 Table. Artwork
supported by figures created with BioRender.com. anti-HBc, antibody to hepatitis B core antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B
surface antigen; HBV, hepatitis B virus; PMTCT, prevention of mother to child transmission; T&T, Test and Treat.
https://doi.org/10.1371/journal.pmed.1003068.g002
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prevalence values. Among 8 of the remaining studies with the poorest quality evaluations, we
were unable to evaluate quality of laboratory methods in 7 cases because the journals in ques-
tion did not support electronic archives dating back far enough to access the full publication,
but relevant serological parameters were available from the abstract.
The quality assessment (online at Figshare: 10.6084/m9.figshare.6154598) and Forest Plots
of the data (S1 Fig) highlighted differences in our confidence in assessment of prevalence of
HBsAg and anti-HBc, with sufficient sample sizes reported by 83% and 53% of all included
studies for these 2 parameters, respectively. In almost all cases (n = 108), HBsAg and anti-HBc
were measured in the same cohorts, and the anti-HBc prevalence was frequently considerably
higher than the HBsAg, generally requiring larger cohort sizes to ascertain similar levels of
confidence. A number of studies reported powering their analysis for assessing HBsAg preva-
lence, but this was infrequently considered for anti-HBc.
Prevalence of infection (HBsAg) is positively correlated with exposure
(anti-HBc)
Cohort spatial distribution and associated serological markers are shown in Fig 3 and can be
visualised using our interactive tool online [29]. Pooling data for all regions, the prevalence of
CHB was positively correlated with exposure (R2 = 0.45, p< 0.001 by weighted linear regres-
sion) (Fig 4A). Prevalence of CHB differs significantly between regions (Fig 4B–4F). Focusing
specifically on Uganda, we also found a significant relationship between CHB prevalence and
exposure (p = 0.006, Fig 4G), although considerable CHB prevalence/exposure ratio variation
is seen between different Ugandan studies.
There are striking differences in seroprevalence by country (Fig 5A) and by region (Fig 5B).
For example, HBsAg prevalence in Northern Africa is lower compared to Western and South-
ern Africa (p< 0.001 and p = 0.007, respectively, Fig 5B), but this difference cannot be
explained only by lower population exposure (anti-HBc) rates: although exposure is lower in
Northern than Western Africa (p< 0.001), there is no difference in exposure between Southern
and Northern Africa (p = 0.5). Indeed, the predicted CHB prevalence was generally 30% to 40%
lower in Northern than Southern Africa for any given exposure (Fig 4D and 4E; S3 Table). Cen-
tral African regions display a different relationship between HBsAg and anti-HBc, compared to
other settings whereby high exposure is not associated with a correspondingly high prevalence
of CHB infection (Fig 4C). This is likely to be a robust representation of the region, as the data
are presented by 14 studies published over a 16-year period and represent multiple countries in
which a median of 383 individuals were analysed (IQR 201–772 individuals).
We did not find any significant differences in prevalence or exposure between HIV-positive
cohorts (n = 27) and all other cohorts (n = 79; both p> 0.05; S2 Fig). In 3 studies that assessed
both HIV-positive and HIV-negative cohorts, CHB prevalence was consistently higher among
HIV-positive patients (mean 2.23-fold) [30–32]. Exposure was also higher in HIV-positive
cohorts than in HIV-negative cohorts for two-thirds of studies [31, 32]. In a third study in
South Africa, exposure was similar irrespective of HIV status, suggesting that the increased
CHB prevalence in the HIV-positive cohort was the result of reduced clearance rates relative
to the HIV-negative cohort [30].
Impact of catch-up vaccination of adolescents and adults in highly endemic
settings
We did not identify any published evidence or specific recommendations for catch-up of ado-
lescents and adults. However, a number of authors suggest catch-up programmes as a way of
PLOS MEDICINE HBV seroepidemiology data for Africa
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003068 April 21, 2020 8 / 22
Fig 3. Maps demonstrating the location and HBV seroepidemiology of adult cohorts identified through a systematic literature review. First row
shows data by individual cohort, depicting (A) HBsAg prevalence, (B) anti-HBc prevalence (exposed plus infected), and (C) HBV susceptible
population (100% of population minus anti-HBc prevalence). Each circle is placed to represent the location of the cohort. Second row shows data by
country (D–F) and third row by region (G–I). Each area is coloured to reflect high to low prevalence of the attribute in question (scale bar as shown on
each panel). Countries shown in grey have no data. The cohort metadata are available online at Figshare: 10.6084/m9.figshare.6154598, and an
interactive version of these maps can be accessed online [29]. Outline maps available as open source from http://www.maplibrary.org/library/index.
htm. Anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
https://doi.org/10.1371/journal.pmed.1003068.g003
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tackling high HBV prevalence [3, 16, 33, 34] (all the relevant studies and recommendations are
summarised in S4 Table).
Based on combining the mean prevalence values from Uganda cohorts to provide a broad
overview, 54% of adults across this country have been exposed to HBV (among these, 11% of
adults are actively HBV infected, and the remainder have serological evidence of resolved
infection). This leaves 46% of the total adult population potentially susceptible (orange bars,
Fig 5A). Only a small proportion of this susceptible pool of adults would be exposed to HBV
infection each year (estimated in another East African study at 3%–4%) [35]. The natural his-
tory of infection in otherwise healthy adults suggests that <5% of exposure events lead to
Fig 4. Relationship between population prevalence of anti-HBc (exposure) and HBsAg (active infection) for different regions of Africa. Data are
shown for (A) the entire African continent; for (B) Western, (C) Central, (D) Northern, (E) Southern, and (F) Eastern Africa; and for (G) Uganda.
These data are derived from a review of the published literature, using UN geoschemes to classify the geographic regions [24]. R2 and p-values by
weighted linear regression (solid line), with studies weighted by cohort size. Outer dashed lines show 95% confidence intervals. Weighted linear
regression plots and 95% CIs (shaded regions) are shown for the whole of Africa in red, for each region in grey. Linear regression lines of fit in plots B–
G have been shown together with the fit for the whole continent for comparison. In each plot, the dots represent only studies associated with that
region. Anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; UN, United Nations.
https://doi.org/10.1371/journal.pmed.1003068.g004
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CHB. Thus, the proportion of the total adult population predicted to avoid CHB through
catch-up vaccination each year is, roughly, 50% (vulnerable) × 4% (exposed) × 5% (develop
chronicity) = 0.1%.
Using our HBV dynamic model (summarised in Fig 2, and with details previously pub-
lished [9]), we investigated the impact of catch-up vaccination among adults within a high-
prevalence setting, exemplified by Uganda [3] (based on parameters listed in S1 Table). The
predicted short-term impact of interventions is shown in Fig 6A–6E with longer-term predic-
tions in Fig 6F. While projecting that catch-up vaccination of all individuals mediates an esti-
mated 16% reduction over 50 years (Fig 6A)—and routine catch-up vaccination of the age
group >6 years is predicted to bring about an 11% reduction (Fig 6B)—it is noteworthy that
the impact of this strategy disappears over longer time scales (Fig 6F). This decline in impact is
due to a limited pool of susceptible adults and the lack of direct impact on the actively infected
population. In the long term, this suggests that the strategy offers no sustained overall benefit
in progress towards elimination targets, even when deployed at 100% coverage. In contrast,
our projections suggest that enhanced coverage of other interventions—including infant
immunisation (Fig 6C) and PMTCT (Fig 6D)—could lead to much higher impact, both in the
shorter and longer terms.
Impact of T&T in highly endemic settings
We investigated the projected impact of T&T, concluding that it has the highest impact of the
modelled interventions; at 100% coverage, this leads to 33% reduction in prevalence by 20
Fig 5. Estimated proportion of the population with chronic HBV infection (HBsAg), total exposure (anti-HBc), and susceptibility to HBV
infection, divided by (A) country and (B) region of Africa. Countries have been grouped by region according to the UN geoscheme for Africa [24].
The number of studies per country is given in brackets next to the country name. Two studies were counted twice as they contained cohorts from 2
different countries. Per-country estimations were calculated, weighting individual studies according to cohort size. In panel (B), boxplots show the
weighted estimations of prevalence with 95% confidence intervals, with significant differences indicated. See methods for definitions of infection,
previous exposure, and susceptibility. Anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; UN,
United Nations.
https://doi.org/10.1371/journal.pmed.1003068.g005
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years (95% CI 30%–37%) and 62% at 50 years (95% CI 57%–68%) (Fig 6E). Recognising the
significant barriers to identifying all cases of CHB (which include silent infection, lack of edu-
cation and awareness, poor access to clinical and laboratory facilities, and stigma [2, 36, 37]),
we also modelled the outcome for T&T strategies that reach<100% of the population. Diagno-
sis and treatment for 80% of infected adults or 50% of the whole infected population (Fig 6E,
dashed lines) still deliver a projected reduction in prevalence over time that is comparable to
infant immunisation (Fig 6F). Even reducing the target to only 50% of adults (Fig 6E) is still
substantially more effective than 100% catch-up vaccination (Fig 6A).
Discussion
Summary of main findings
In this study, we set out to evaluate the relationship between the prevalence of CHB infection
and exposure in different settings. We suggest that determinants of CHB prevalence involve
numerous factors, including age at exposure (Fig 7A), route of infection, host genetics, and
viral genotype, and interactions between them remain poorly understood. Using a data set
Fig 6. Decline in HBsAg prevalence over time in response to population interventions for HBV infection in Uganda. Decline in prevalence is
shown over time starting at approximately 10% as used for model fitting to the Uganda setting (see main text). Shaded areas show 95% confidence
interval for each intervention based on 5,000 stochastic simulations using parameter samples from the posteriors obtained by fitting the model.
Comparisons of interventions applied to 100% of the population: (A) catch-up vaccination of all ages as a one-off event at time = 0 (orange); (B) routine
immunisation of children as they reach 6 years of age (proxy for school age) (green); (C) routine neonatal immunisation (blue); and (D) PMTCT
interventions for all births (combining accelerated neonatal immunisation with HBIg and antiviral therapy in pregnant mothers, red). (E) Comparison
of a T&T approach applied to different proportions of the population: 50% of individuals older than 6 years, 80% of individuals older than 6 years, 50%
of population, 80% of population, and 100% of population (purple solid line). This demonstrates the impact of reduced proportions of the population
exposed to drug therapy, as a result of either not having drug prescribed or noncompliance with prescribed therapy. (F) Interventions shown in A–E
applied to 100% of the population were run for an extended time period of 500 years to observe long-term effects. The numbers at time points t = 20
and t = 50 years, incorporating an overall timeframe that includes the 2030 elimination targets, show the mean reduction in HBsAg prevalence achieved
for each of the interventions: (A) 11% (95% CI 9%–15%) and 16% (13%–20%); (B) 3% (2%–5%) and 11% (9%–15%); (C) 14% (12%–18%) and 39%
(34%–47%); (D) 13% (10%–15%) and 31% (25%–35%); and (E) 33% (30%–37%) and 62% (57%–68%). HBIg, hepatitis B immunoglobulin; HBsAg,
hepatitis B surface antigen; HBV, hepatitis B virus; PMTCT, prevention of mother to child transmission; T&T, Test and Treat.
https://doi.org/10.1371/journal.pmed.1003068.g006
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gathered via a systematic review, and applying an existing mathematical model, we evaluated
the impact of several intervention approaches in a high-prevalence setting (Uganda). Our anal-
ysis suggests that catch-up vaccination is of limited impact in this setting and that T&T is pre-
dicted to have a much greater, sustained impact that performs most consistently across
Fig 7. Cartoons to illustrate seroepidemiology of HBV infection in Africa and the differential impact of HBV interventions according to
population targeted. (A) After exposure to HBV, the risk of developing CHB is highest among young infants, and this risk gradually declines with age
until adulthood, when there is low risk of developing CHB. Figure informed by parameters in S1 Table. Artwork supported by figures created with
BioRender.com. (B) Populations from Sudan [39], Uganda [3], and Burkina Faso [40] represent approximately the 25th, 50th, and 75th percentiles in
the data set collected from our literature review. In adults, assuming that different populations are exposed at the same rate and the risk of CHB is
constant (estimated to be 5% in healthy adults as shown in panel A), the incidence of new CHB infection in the population is related to the proportion
S. Without intervention, 100% of predicted new cases will occur. If 50% of the adult population is vaccinated in a catch-up campaign, CHB will be
prevented only among the population S. The impact of catch-up vaccination on incidence is therefore related to S, with reduced impact in highly
exposed populations. In a T&T scenario, with 50% of cases identified and treated, incidence is consistently reduced, regardless of S. anti-HBc, antibody
to hepatitis B core antigen; C, HBsAg prevalence; CHB, chronic hepatitis B; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; R, anti-HBc
prevalence; S, susceptible population; T&T, Test and Treat.
https://doi.org/10.1371/journal.pmed.1003068.g007
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settings (Fig 7B). Careful, evidence-based deployment of interventions is essential if sustained
and collective progress is to be made towards targets set by the SDGs [7]. Findings of this
study highlight the requirement to tailor intervention strategies based on well-informed, high-
resolution epidemiological data. This is all the more important for resource-limited settings
that are underrepresented in the existing evidence base [38].
Insights into interventions
The importance of infant vaccination remains paramount and has been well validated in clini-
cal practice, mathematical models, and population epidemiology across diverse settings. In
this study, we set out to explore the controversial and less studied approaches of catch-up vac-
cination and T&T. Although it can seem intuitive to deploy catch-up vaccination for adoles-
cents and adults in high-prevalence settings, only a limited proportion of the population
remains susceptible, such that only a minority will benefit from the intervention. Thus, the
effectiveness of catch-up is expected to be greater in low-prevalence populations. For this rea-
son, catch-up will frequently not be a prudent use of resources, although in some settings there
may be cost benefits in targeting young populations [41], and vaccination may be even more
important in regions where hepatitis delta virus (HDV) co-infection is highly prevalent [42].
In contrast, our data suggest that T&T programmes aimed at older children and adults may
have great impact, in keeping with the findings of a recent review of vaccination [34] and with
economic evaluations [43]. Achieving success through T&T requires multipronged investment
including education, laboratory infrastructure, and provision of effective, sustained drug ther-
apy for both HBV infection and HIV/HBV coinfection. Focus on diagnosis is prerequisite [19,
44], parallel investment in infrastructure is required to triage cases for treatment (based on
including laboratory and radiological criteria), and scrutiny will be required for drug resis-
tance [45].
The epidemiology and dynamics of infection are different in certain high-risk subgroups
(healthcare workers, partners and household contacts of infected individuals, sex workers and
their clients, men who have sex with men), and continuing to target these individuals with pre-
ventive vaccination remains very important. Likewise, we continue to emphasise the impor-
tance of routine infant immunization campaigns, which are a cornerstone of elimination
strategies [9].
Reasons for regional differences in HBV epidemiology in Africa
As exemplified in this study by the case of Uganda, we find evidence of region-specific differ-
ences in exposure, transmission, and chronicity rates. This is consistent with patterns previ-
ously described in the literature, with the potential for marked differences in seroepidemiology
even between neighbouring villages [46]. A diverse range of factors influence the risk of devel-
oping chronicity after acute infection (Table 1), with age at exposure among the most robustly
recognised. Our data suggest that in regions with low CHB prevalence but high exposure (e.g.,
central Africa), most exposure events may be occurring in adults. In contrast, in Western
Africa, the majority of exposure events may be in early life. Careful data collection and review
is required to underpin the most effective interventions for specific locations. HBV genotype
may also influence local seroepidemiology, given variations in spatial distributions and geno-
type-specific epidemiological factors such as variations in transmission potential [47–49]. Like-
wise, traditional cultural practices that confer exposure to HBV may be common in some
regions but not others [50].
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Relationship between HBV and HIV
We found no evidence that HIV-positive individuals were more likely to be HBV infected or
exposed, in keeping with previous reports [49]. This observation reflects different transmission
patterns: HIV is less infectious than HBV when transmitted by blood and is largely sexually
transmitted in Africa. In contrast, the risk of developing CHB is high in early life and declines
with age. However, robust analysis of the influence of HIV on HBV exposure and acquisition
is made difficult by limited data. While we were able to identify a large number of HIV-posi-
tive cohorts, only 3 of these had directly comparable HIV-negative cohorts. Among all other
published cohorts, which we have assumed to be HIV negative, a background prevalence of
HIV infection is likely but not clearly reported.
T&T in the context of HBV guidelines
Current guidelines for the management of CHB recommend treatment only in certain sub-
groups, based on risk of liver disease [13]. Thus, deployment of a universal T&T campaign,
as modelled in this study (see Methods), would treat many individuals who do not meet cur-
rent criteria. The infrastructure and budgets to support this detailed individual assessment
Table 1. Factors that may contribute to regional differences in prevalence of anti-HBc and HBsAg across Africa.
Factor Rationale for contribution to regional differences in HBV seroepidemiology
Circulating HBV viral
genotype
• Predominant genotype varies by region, with genotype-A common in
Southern Africa, genotype-D in the North, and genotype-E in the West [51].
Host ethnicity and genetics • HLA-type and T-cell repertoire have been linked to the ability to control the
infection [52–54].
Transmission differences • Subtle differences in the transmission patterns (vertical versus horizontal) of
the HBV genotypes have been documented.
• Transmission route is fundamentally linked to age at exposure [55].
Age at exposure • The probability of developing chronic HBV after exposure is strongly
associated with age [56]. Populations with a younger age at exposure are
therefore likely to have a higher HBsAg prevalence relative to the anti-HBc
prevalence.
Coinfection within population • Risk factors for acquisition of blood-borne viruses overlap between HIV, HBV,
and HCV.
• Egypt and the Nile Delta have some of the highest reported prevalences of
HCV globally. Coinfection of HBV and HCV has been linked to spontaneous
clearance of HCV although evidence of the impact on HBV remains scarce [57,
58].
Political instability • Central Africa includes several regions disrupted by recent conflict and
resulting population migration, with powerful influence on increases in
interpersonal violence and sexual assault, reduced access to barrier
contraception, inadequate screening of blood products, and reduced access to
healthcare, all of which can increase exposure rates in the adult population.
Traditional cultural practices • Exposure to blood-borne viruses is influenced by traditional healing practices,
scarification, piercing, tattooing, and nonsterile surgical practice.
Uptake of HBV vaccination in
the region
• Countries with earlier uptake of the HBV vaccine are likely to have lower anti-
HBc and HBsAg prevalence than countries that implemented the vaccine later.
• Prevalence of vaccine escape mutants may contribute, although data for Africa
are scarce [45].
Abbreviations: anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B
virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HLA, human leukocyte antigen
https://doi.org/10.1371/journal.pmed.1003068.t001
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are not available in many lower- and middle-income country settings, and there is a call for
algorithms to be simplified [59, 60]. Relaxing the stringency of assessment for treatment may
also have the added benefit of reducing complications from HBV progression, as not all indi-
viduals at high risk of cirrhosis or hepatocellular carcinoma (HCC) are detected by current
algorithms [61]. Therefore, adopting a universal T&T strategy for HBV would need to be care-
fully evaluated to consider challenges and risks as well as benefits. Wider deployment of NA
therapy involves a need for expanded infrastructure, imposes economic costs, and carries risks
of drug side effects and toxicity, as well as raises concerns about nonadherence and the associ-
ated potential for increasing the selection of drug resistance [45]. However, these may be offset
by the benefits of individual, societal, and economic benefits of reducing the morbidity and
mortality of chronic liver disease, as well as the population gains of minimising the risk of
transmission.
Caveats and limitations
Our maps highlight important geographical gaps in HBV data (Fig 3); furthermore, existing
cohorts are often relatively small and biased by the recruitment of specific groups. The pub-
lished literature does not account for the prevalence of occult HBV, which is rarely detected
due to lack of availability and high cost of DNA testing. However, individuals with occult HBV
would still generate anti-HBc; thus, while we may be underestimating the prevalence of active
infection, these individuals are still included within our exposed population.
We considered individuals to have cleared HBV if they were HBsAg negative and anti-HBc
positive. However, a proportion of these individuals may still harbour HBV cccDNA in their
liver and are at risk of reactivation, particularly in the context of immunosuppression. T&T
strategies (whether using HBsAg and/or HBV DNA) would not identify these individuals, and
therefore improved diagnostics and monitoring may be of benefit in high-risk populations.
We did not include data for antibody to HBsAg (anti-HBs) prevalence (immunised popula-
tion) because a limited number of papers report these together with anti-HBc and HBsAg
data. The most common reason for study exclusion from the literature review was no anti-
HBc prevalence reported (Fig 1). The sensitivity and specificity of serological assays vary [62],
which may represent a source of bias or uncertainty in our data set, although our quality
appraisal of the literature shows that methods were robustly reported overall. However, mak-
ing the inclusion criteria more stringent would have limited the number of studies we could
include, potentially limiting our overall findings.
Based on the age of adults represented in most of our cohorts and vaccination starting in
1995, we can assume that the majority of participants in the study were unlikely to have been
vaccinated in infancy. Future sero-surveys will provide more insights into the impact of rou-
tine infant vaccination. We focused on adult populations only, because the age-associated risk
of developing chronic HBV is a confounding factor in younger cohorts, making inference
about the anti-HBc prevalence challenging across multiple age groups. It would be of interest
to determine age-specific prevalence of HBsAg and anti-HBc because age is likely to be an
important source of heterogeneity. However, metadata are poorly reported, and we were
unable to disaggregate serological data by age.
Our modelled universal T&T intervention does not stratify individuals for therapy but
works on the basis of treating anyone who is HBsAg positive. In current clinical practice,
guidelines recommend treatment only in the context of high viral load and/or evidence of
inflammatory liver disease [13]. However, explicitly stratifying population subgroups for T&T
within our framework would have required the inclusion of clinical classes (e.g., liver transam-
inases, fibroscan scores), which would have added significant uncertainty. Our model
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framework does not include explicit age-specific or risk-group assumptions regarding force of
transmission, and again we argue that little data exist to inform this parameterization. Despite
uncertainty in specific variables, the model fixes certain parameters, based on estimates from
the literature (e.g., HBeAg is set at 27%, recognising that the confidence intervals around this
point estimate are wide and vary between settings [63, 64]). Our projections are not intended
to be exact quantifications of impact over time but serve as a means of comparing the dynamic
and nonlinear outcomes of different strategies.
While we have considered HIV as a precedent for T&T interventions, there are also impor-
tant differences between HIV and HBV, namely the lack of an HIV vaccine and the shorter
average timeframes over which morbidity and mortality evolve in the setting of HIV infection.
Implications for future investigation and practice changes
Our data show the potential value of T&T approaches for HBV, building both on experience
gained from HIV and on insights into paediatric interventions that we have previously mod-
elled [9]. Further analysis is required to investigate more specifically the populations or con-
texts in which vaccination strategies or T&T might best be deployed, and the extent to which
this intervention is synergistic with other routine interventions (infant vaccination and
PMTCT). We advocate significant investment in capacity building for improving HBV diag-
nosis and treatment, including point-of-care testing, antenatal screening, and provision of
TDF. A sustained and systematic commitment to diagnosis and treatment represents a key
component of the journey towards HBV elimination.
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